Canopy Growth Corp Stock
-
Your prediction
Canopy Growth Corp Stock
Pros and Cons of Canopy Growth Corp in the next few years
Pros
Cons
Performance of Canopy Growth Corp vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Canopy Growth Corp | - | - | - | - | - | - | - |
Bausch Health Companies Inc. | 2.160% | 12.510% | 15.742% | 42.361% | 35.362% | -62.595% | -55.196% |
Catalent Inc. | 0.380% | 1.751% | -2.243% | -16.360% | 26.942% | -39.885% | 44.875% |
Opko Health Inc. | 10.430% | 29.918% | 21.081% | -13.001% | -22.049% | -70.660% | -49.046% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on a first impression of the financials of Canopy Growth, a leading company in the pharmaceutical industry, it is evident that the company has faced some difficulties in recent years. With net losses reported in the last three years and a negative gross profit, the company appears to be struggling in terms of revenue generation and operational efficiency. However, there are still positive aspects such as a strong cash position and a manageable level of debt. The following in-depth analysis highlights the pros and cons of Canopy Growth's financial performance to better understand its overall position in the market.
*Pros: *
Significant cash and short-term investments: Canopy Growth has a strong cash position, as shown by the most recent quarterly balance sheet, which reports CAD 769.5 million in cash and short-term investments amounting to CAD 1.22 billion. This provides financial stability and the flexibility to pursue growth opportunities or address unforeseen challenges.